UBS Group AG - EVOKE PHARMA INC ownership

Back to all holdings Add to watchlist

EVOKE PHARMA INC's ticker is and the CUSIP is 30049G203. A total of 13 filers reported holding EVOKE PHARMA INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.0%.

Links
Filings
Quarter-by-quarter ownership
UBS Group AG ownership history of EVOKE PHARMA INC
ValueSharesWeighting
Q3 2023$3,736
+104.5%
2,707
+144.5%
0.00%–
Q2 2023$1,827
-13.1%
1,1070.0%0.00%–
Q1 2023$2,103
-29.1%
1,1070.0%0.00%–
Q4 2022$2,967
+48.4%
1,1070.0%0.00%–
Q3 2022$2,000
-89.5%
1,107
-80.7%
0.00%–
Q2 2022$19,000–5,722–0.00%–
 Download
Other shareholders
EVOKE PHARMA INC shareholders Q2 2022
NameSharesValueWeighting ↓
Tower Research Capital LLC (TRC) 3,985$80.00%
Concord Wealth Partners 114$2170.00%
Renaissance Technologies 11,178$210.00%
ROYAL BANK OF CANADA 28$00.00%
VANGUARD GROUP INC 29,851$56,7170.00%
UBS Group AG 1,107$2,1030.00%
NewEdge Advisors, LLC 208$3950.00%
WELLS FARGO & COMPANY/MN 16$300.00%
CONCOURSE FINANCIAL GROUP SECURITIES, INC. 0$00.00%
GEODE CAPITAL MANAGEMENT, LLC 20,894$39,6980.00%
View complete list of EVOKE PHARMA INC shareholders